SKYEClinical Trials•globenewswire•
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
Sentiment:Neutral (60)
Summary
(NASDAQ:SKYE) Skye also announces completion of enrollment of 26‑week extension study; 52‑week data planned, with post‑extension 13‑week follow‑up Skye also announces completion of enrollment of 26‑week extension study; 52‑week data planned, with post‑extension 13‑week follow‑up
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 2, 2025 by globenewswire